Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
CHINA OILFIELD
02883
5
CNOOC
00883
CN Stock MarketDetailed Quotes
Wuhan Hiteck Biological Pharma (300683)
- 32.84
- +0.60+1.86%
Market Closed Apr 24 15:00 CST
4.30BMarket Cap-17.89P/E (TTM)
33.02High32.00Low61.33KlotVolume32.26Open32.24Prev Close199.88MTurnover5.02%Turnover RatioLossP/E (Static)130.89MShares61.7652wk High2.01P/B4.01BFloat Cap21.4552wk Low38.69Limit Up122.06MShs Float84.71Historical High25.79Limit Down3.16%Range %18.67Historical Low0.13Dividend TTM32.59Avg Price28.42KlotAsk0.40%Div Yield TTM100Lot Size30.66KlotBid
Wuhan Hiteck Biological Pharma (300683) Income Statement
All
YOY
| (Q1)Mar 31, 2026 | (FY)Dec 31, 2025 | (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 1.52%159.05M | -16.57%541.45M | -6.45%421.9M | -3.36%275.06M | 18.79%156.67M | 7.75%648.97M | 2.87%450.99M | -0.64%284.62M | -4.87%131.89M | -12.54%602.28M |
| Operating revenue | 1.52%159.05M | -16.57%541.45M | -6.45%421.9M | -3.36%275.06M | 18.79%156.67M | 7.75%648.97M | 2.87%450.99M | -0.64%284.62M | -4.87%131.89M | -12.54%602.28M |
| Other operating revenue | ---- | -68.40%1.03M | ---- | -91.57%403.11K | ---- | -58.06%3.27M | ---- | -46.91%4.78M | ---- | -1.04%7.8M |
| Total operating cost | 3.08%178.2M | -9.06%673.43M | -3.77%513.07M | -1.84%334.85M | -6.86%172.86M | 3.67%740.49M | 5.37%533.19M | 3.46%341.12M | 20.19%185.59M | 3.34%714.28M |
| Operating cost | 12.32%97.87M | -16.27%310.57M | -0.60%245.49M | 5.62%163.01M | 9.95%87.13M | 7.49%370.92M | 0.92%246.97M | -6.28%154.34M | 1.67%79.25M | -2.77%345.06M |
| Operating tax surcharges | -14.47%1.39M | 13.99%8.1M | 24.37%6.26M | 33.25%4.5M | 14.11%1.62M | 29.93%7.11M | 28.80%5.04M | 23.65%3.38M | 23.93%1.42M | -2.96%5.47M |
| Operating expense | -0.62%34.19M | 23.33%156.14M | 15.53%115.71M | 13.19%72.51M | 23.79%34.4M | -1.60%126.61M | 0.84%100.16M | -5.13%64.06M | -11.48%27.79M | 1.55%128.66M |
| Administration expense | 8.41%25.88M | -3.48%115.11M | -12.77%82.98M | -18.65%50.52M | -51.71%23.87M | 5.23%119.26M | 30.18%95.13M | 28.27%62.11M | 114.77%49.44M | 20.80%113.33M |
| Financial expense | 53.18%-550.42K | 8.01%-4.72M | -18.39%-3.71M | -39.27%-2.41M | -386.69%-1.18M | 28.11%-5.13M | 45.43%-3.14M | 63.66%-1.73M | 92.64%-241.53K | 36.51%-7.14M |
| -Interest expense (Financial expense) | -36.87%266.56K | -39.46%1.39M | -47.76%1.07M | -47.01%748.3K | -64.48%422.27K | -4.11%2.3M | 19.42%2.05M | 29.68%1.41M | 222.14%1.19M | 114.35%2.39M |
| -Interest Income (Financial expense) | 46.13%-920.58K | 21.21%-6.41M | 15.49%-4.74M | 4.91%-3.36M | -5.69%-1.71M | 18.54%-8.14M | 27.97%-5.61M | 42.13%-3.53M | 57.45%-1.62M | 22.29%-9.99M |
| Research and development | -28.08%19.43M | -27.52%88.24M | -25.50%66.33M | -20.77%46.72M | -3.31%27.01M | -5.55%121.75M | -1.88%89.03M | 15.33%58.97M | 15.47%27.94M | 6.15%128.9M |
| Credit Impairment Loss | 5,061.62%1.37M | 79.99%-1.5M | 13.51%368.29K | -49.44%365.09K | -95.31%26.48K | -667.79%-7.49M | -84.99%324.45K | -65.49%722.16K | -40.39%564.6K | 74.31%-974.97K |
| Asset Impairment Loss | -180.89%-8.78M | -480.24%-122.7M | -6,232.98%-105.58M | -406.99%-7.17M | -117.66%-3.13M | 64.83%-21.15M | -198.90%-1.67M | -145.44%-1.41M | 370.69%17.7M | -81.03%-60.12M |
| Other net revenue | -615.16%-7.02M | -745.89%-102.12M | -335.30%-77.41M | -38.53%17.03M | -94.72%1.36M | 150.87%15.81M | 34.08%32.9M | 35.29%27.71M | 179.60%25.81M | -635.32%-31.08M |
| Fair value change income | -72.10%513.13K | -1,277.71%-12.52M | 55.91%7.2M | -15.84%5.14M | -68.33%1.84M | -147.88%-908.85K | -60.34%4.62M | -10.43%6.1M | 149.25%5.81M | -85.02%1.9M |
| Invest income | -167.01%-269.89K | 23.62%20.64M | 72.99%13.03M | 210.80%12.69M | 68.44%402.76K | 6.46%16.7M | 152.12%7.53M | 90.13%4.08M | 10,050.76%239.11K | 42.06%15.69M |
| -Including: Investment income associates | ---- | -751.89%-10.1M | ---- | ---- | ---- | 57.16%-1.19M | ---- | ---- | ---- | -15.16%-2.77M |
| Asset deal income | ---2.14M | -1,401.40%-979.18K | -2,143.67%-1.01M | 98.68%-572.48 | ---- | 81.82%-65.22K | 97.93%-45.09K | -210.95%-43.5K | -210.95%-43.5K | -282.04%-358.67K |
| Other revenue | 3.16%2.29M | -47.98%14.94M | -61.23%8.58M | -67.09%6.01M | 43.74%2.22M | 124.49%28.72M | 168.98%22.13M | 190.92%18.26M | -28.26%1.54M | 39.69%12.79M |
| Operating profit | -76.47%-26.17M | -209.21%-234.1M | -241.90%-168.58M | -48.51%-42.75M | 46.82%-14.83M | 47.08%-75.71M | -14.47%-49.31M | -26.34%-28.79M | -325.78%-27.89M | -1,997.07%-143.07M |
| Add:Non operating Income | 440.94%235.74K | 300.42%463.86K | 20.65%268.39K | 116.07%71.19K | 1,063.38%43.58K | -32.67%115.85K | 82.57%222.45K | -70.62%32.95K | -96.16%3.75K | -59.40%172.06K |
| Less:Non operating expense | -13.59%895.9K | 12.68%5.12M | 45.10%3.56M | 132.81%1.67M | 85.40%1.04M | -49.96%4.55M | -60.54%2.45M | -64.98%716.34K | 54.39%559.25K | 537.43%9.09M |
| Total profit | -69.56%-26.83M | -197.93%-238.76M | -233.48%-171.87M | -50.49%-44.35M | 44.37%-15.82M | 47.27%-80.14M | -4.81%-51.54M | -19.22%-29.47M | -317.39%-28.45M | -1,842.57%-151.99M |
| Less:Income tax cost | -106.13%-2.9M | 47.68%-3.33M | -17.63%-10.99M | 17.57%-4.15M | 87.16%-1.41M | 73.17%-6.37M | 52.24%-9.34M | 57.73%-5.03M | -114.80%-10.95M | -32,106.33%-23.74M |
| Net profit | -66.00%-23.93M | -219.14%-235.43M | -281.25%-160.88M | -64.50%-40.2M | 17.57%-14.42M | 42.48%-73.77M | -42.48%-42.2M | -90.68%-24.44M | -919.75%-17.49M | -1,523.72%-128.24M |
| Net profit from continuing operation | -66.00%-23.93M | -219.14%-235.43M | -281.25%-160.88M | -64.50%-40.2M | 17.57%-14.42M | 42.48%-73.77M | -42.48%-42.2M | -90.68%-24.44M | -919.75%-17.49M | -1,523.72%-128.24M |
| Less:Minority Profit | -81.93%-886.89K | 5.81%-4.16M | -13.66%-2.79M | 38.93%-1.02M | 48.48%-487.48K | 40.42%-4.42M | 22.73%-2.45M | 0.90%-1.67M | -288.92%-946.15K | -221.02%-7.42M |
| Net profit of parent company owners | -65.44%-23.05M | -233.48%-231.27M | -297.78%-158.09M | -72.10%-39.18M | 15.81%-13.93M | 42.60%-69.35M | -50.32%-39.74M | -104.58%-22.77M | -1,024.00%-16.55M | -761.20%-120.82M |
| Earning per share | ||||||||||
| Basic earning per share | -63.64%-0.18 | -233.96%-1.77 | -303.33%-1.21 | -76.47%-0.3 | 15.38%-0.11 | 43.01%-0.53 | -42.86%-0.3 | -88.89%-0.17 | -550.00%-0.13 | -745.45%-0.93 |
| Diluted earning per share | -63.64%-0.18 | -233.96%-1.77 | -303.33%-1.21 | -76.47%-0.3 | 15.38%-0.11 | 43.01%-0.53 | -42.86%-0.3 | -88.89%-0.17 | -550.00%-0.13 | -745.45%-0.93 |
| Other composite income | ||||||||||
| Total composite income | -66.00%-23.93M | -219.14%-235.43M | -281.25%-160.88M | -64.50%-40.2M | 17.57%-14.42M | 42.48%-73.77M | -42.48%-42.2M | -90.68%-24.44M | -919.75%-17.49M | -1,523.72%-128.24M |
| Total composite income of parent company owners | -65.44%-23.05M | -233.48%-231.27M | -297.78%-158.09M | -72.10%-39.18M | 15.81%-13.93M | 42.60%-69.35M | -50.32%-39.74M | -104.58%-22.77M | -1,024.00%-16.55M | -761.20%-120.82M |
| Total composite income of minority owners | -81.93%-886.89K | 5.81%-4.16M | -13.66%-2.79M | 38.93%-1.02M | 48.48%-487.48K | 40.42%-4.42M | 22.73%-2.45M | 0.90%-1.67M | -288.92%-946.15K | -221.02%-7.42M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | Zhongshen Zhonghuan Certified Public Accountants (Special General Partnership) | -- | -- | -- | Zhongshen Zhonghuan Certified Public Accountants (Special General Partnership) | -- | -- | -- | Zhongshen Zhonghuan Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
Signs of restarting the second round of US-Iran talks have emerged. According to reports, Iran's foreign minister arrived in Pakistan on Fri
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm